HIV infection drives interferon signaling within intestinal SARS-CoV-2 target cells

Rabiah Fardoos, Osaretin E. Asowata, Nicholas Herbert, Sarah K. Nyquist, Yenzekile Zungu, Alveera Singh, Abigail Ngoepe, Ian Mbano, Ntombifuthi Mthabela, Dirhona Ramjit, Farina Karim, Warren Kuhn, Fusi Madela, Vukani T. Manzini, Frank Anderson, Bonnie Berger, Tune H. Pers, Alex K. Shalek, Alasdair Leslie, Henrik N. KløverprisJCI 2021 · DOI

Abstract

SARS-CoV-2 infects epithelial cells of the human gastrointestinal (GI) tract and causes related symptoms. HIV infection impairs gut homeostasis and is associated with an increased risk of COVID-19 fatality. To investigate the potential link between these observations, we analyzed single-cell transcriptional profiles and SARS-CoV-2 entry receptor expression across lymphoid and mucosal human tissue from chronically HIV-infected individuals and uninfected controls. Absorptive gut enterocytes displayed the highest coexpression of SARS-CoV-2 receptors ACE2, TMPRSS2, and TMPRSS4, of which ACE2 expression was associated with canonical interferon response and antiviral genes. Chronic treated HIV infection was associated with a clear antiviral response in gut enterocytes and, unexpectedly, with a substantial reduction of ACE2 and TMPRSS2 target cells. Gut tissue from SARS-CoV-2-infected individuals, however, showed abundant SARS-CoV-2 nucleocapsid protein in both the large and small intestine, including an HIV-coinfected individual. Thus, upregulation of antiviral response genes and downregulation of ACE2 and TMPRSS2 in the GI tract of HIV-infected individuals does not prevent SARS-CoV-2 infection in this compartment. The impact of these HIV-associated intestinal mucosal changes on SARS-CoV-2 infection dynamics, disease severity, and vaccine responses remains unclear and requires further investigation.

Introduction

While COVID-19 is primarily recognized as a respiratory illness, the gastrointestinal (GI) tract is a significant site of infection, with up to 60% of patients experiencing GI symptoms. People living with HIV (PLWH) face a disproportionately high risk of COVID-19 fatality, often linked to chronic inflammation and "leaky gut" syndrome. This study investigates the molecular intersection of these two viruses, specifically whether the chronic immune activation in HIV-infected individuals alters susceptibility to SARS-CoV-2 by modulating entry receptors or inducing a protective antiviral state.

Methods and Datasets

The researchers employed a multi-omic approach to map the cellular landscape of the human GI tract. Using the Seq-Well S3 platform, they generated single-cell RNA sequencing (scRNA-Seq) profiles for 32,381 cells derived from 24 participants in KwaZulu-Natal, South Africa. Tissues sampled included blood, tonsils, lung, duodenum, and mesenteric lymph nodes.

Overview of the multi-tissue single-cell study design and receptor expression profiling.

The analysis integrated lineage tracing via Monocle trajectory analysis to track receptor expression during cell differentiation and multicolor fluorescence immunohistochemistry (F-IHC) to validate protein-level expression. The study compared four groups: HIV-negative controls, HIV-positive individuals on antiretroviral therapy (ART), SARS-CoV-2 infected patients, and HIV/SARS-CoV-2 coinfected individuals.

Key Results and Insights

The Enterocyte as a Primary Target

The study identified absorptive enterocytes in the duodenum as the primary targets for SARS-CoV-2, exhibiting the highest coexpression of the "entry triad": the ACE2 receptor and the proteases TMPRSS2 and TMPRSS4. Expression levels were found to increase as cells matured from stem-like states into terminal absorptive enterocytes.

The HIV Paradox: Antiviral Signaling vs. Viral Entry

Chronic HIV infection was found to drive a robust interferon (IFN) response in the gut. Paradoxically, this "antiviral" state led to a significant reduction in the number of ACE2+ and TMPRSS2+ absorptive enterocytes in PLWH on ART compared to uninfected controls. While fewer receptors might suggest reduced susceptibility, the study found that SARS-CoV-2 successfully infected gut cells in HIV-positive individuals.

Fluorescence immunohistochemistry showing spatial localization of ACE2, TMPRSS2, and EpCAM in the duodenum and colon.

Viral Persistence and Spatial Mapping

F-IHC confirmed that ACE2 expression is highest on the luminal surface of the duodenum but shifts toward the crypt bases in the colon. In a biopsy from an HIV/SARS-CoV-2 coinfected individual, abundant SARS-CoV-2 nucleocapsid protein (NP) was observed colocalized with ACE2, demonstrating that the HIV-induced mucosal changes failed to block viral entry.

Limitations and Future Work

The study's findings are constrained by a relatively small sample size (n=24) and a sex bias, as transcriptomic data were derived exclusively from women. Furthermore, the data were collected prior to the emergence of newer variants like Omicron. Future research is required to determine how these mucosal alterations influence long-term COVID-19 severity, variant dynamics, and vaccine efficacy in populations living with HIV.

Summary updated

Abstract

SARS-CoV-2 infects epithelial cells of the human gastrointestinal (GI) tract and causes related symptoms. HIV infection impairs gut homeostasis and is associated with an increased risk of COVID-19 fatality. To investigate the potential link between these observations, we analyzed single-cell transcriptional profiles and SARS-CoV-2 entry receptor expression across lymphoid and mucosal human tissue from chronically HIV-infected individuals and uninfected controls. Absorptive gut enterocytes displayed the highest coexpression of SARS-CoV-2 receptors ACE2, TMPRSS2, and TMPRSS4, of which ACE2 expression was associated with canonical interferon response and antiviral genes. Chronic treated HIV infection was associated with a clear antiviral response in gut enterocytes and, unexpectedly, with a substantial reduction of ACE2 and TMPRSS2 target cells. Gut tissue from SARS-CoV-2-infected individuals, however, showed abundant SARS-CoV-2 nucleocapsid protein in both the large and small intestine, including an HIV-coinfected individual. Thus, upregulation of antiviral response genes and downregulation of ACE2 and TMPRSS2 in the GI tract of HIV-infected individuals does not prevent SARS-CoV-2 infection in this compartment. The impact of these HIV-associated intestinal mucosal changes on SARS-CoV-2 infection dynamics, disease severity, and vaccine responses remains unclear and requires further investigation.
BibTeX
@inproceedings{fardoos2021hiv,
  author = {Rabiah Fardoos and Osaretin E. Asowata and Nicholas Herbert and Sarah K. Nyquist and Yenzekile Zungu and Alveera Singh and Abigail Ngoepe and Ian Mbano and Ntombifuthi Mthabela and Dirhona Ramjit and Farina Karim and Warren Kuhn and Fusi Madela and Vukani T. Manzini and Frank Anderson and Bonnie Berger and Tune H. Pers and Alex K. Shalek and Alasdair Leslie and Henrik N. Kløverpris},
  title = {{HIV infection drives interferon signaling within intestinal SARS-CoV-2 target cells}},
  booktitle = {JCI},
  year = {2021},
  doi = {10.1172/jci.insight.148920},
}
Figure